An open-label study of quetiapine for delirium.

Simple item page
dc.contributor.authorManeeton, Benchalaken_US
dc.contributor.authorManeeton, Narongen_US
dc.contributor.authorSrisurapanont, Maniten_US
dc.date.accessioned2009-05-27T19:00:56Z
dc.date.available2009-05-27T19:00:56Z
dc.date.issued2007-10-29en_US
dc.descriptionChotmaihet Thangphaet.en_US
dc.description.abstractOBJECTIVE: To evaluate the effects of quetiapine treatment in patients with delirium. MATERIAL AND METHOD: All patients with delirium were assessed. The diagnosis of delirium was confirmed by using the Confusion Assessment Method (CAM). Quetiapine at the dose between 25 and 100 mg/day was given for 7 days. The efficacy of quetiapine on delirium was evaluated by using the Delirium Rating Scale (DRS) and the Clinical Global Impression-Severity scale (CGI-S). The extrapyramidal side effects were assessed by using the Modified (9-item) Simpson-Angus Scale (MSAS). RESULTS: Twenty-two patients had delirium. Seventeen (10 males and 7 females) subjects with a mean age (SD) of 55.6 (18.6) years were included in the present study. Means (SDs) dose and duration (SD) of quetiapine treatment were 45.7 (28.7) mg/day and 6.5 (2.0) days, respectively. The DRS and CGI-S scores of days 2-7 were significantly lower than those of day 0 (p < 0. 001) for all comparisons). Only two subjects were shown to have mild tremor. CONCLUSION: Quetiapine within the range of 25-100 mg/day improves delirious condition within 24 hours of treatment. It is well-tolerated and has a very low propensity to induce extrapyramidal side effects. Further randomized, placebo-controlled trials are warranted.en_US
dc.description.affiliationDepartment of Psychiatry, Chiang Mai University, Chiang Mai, Thailand. bkhongsa@mail.med.cmu.ac.then_US
dc.identifier.citationManeeton B, Maneeton N, Srisurapanont M. An open-label study of quetiapine for delirium. Journal of the Medical Association of Thailand. 2007 Oct; 90(10): 2158-63en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/40300
dc.language.isoengen_US
dc.source.urihttps://www.mat.or.th/journal/all.phpen_US
dc.subject.meshAntipsychotic Agents --adverse effectsen_US
dc.subject.meshBasal Ganglia Diseasesen_US
dc.subject.meshDelirium --drug therapyen_US
dc.subject.meshDibenzothiazepines --adverse effectsen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshNeuropsychological Testsen_US
dc.subject.meshProspective Studiesen_US
dc.subject.meshPsychological Testsen_US
dc.subject.meshPsychometricsen_US
dc.subject.meshTreatment Outcomeen_US
dc.titleAn open-label study of quetiapine for delirium.en_US
dc.typeClinical Trialen_US
dc.typeJournal Articleen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Journal of the Medical Association of Thailand